In the article entitled “Travel vaccines: Update for Canadian pharmacists” [CPJ 2019;152(6):411-7], the following corrections need to be noted to reflect changes to the Canadian product monograph for the Japanese encephalitis vaccine effective March 2018:
Table 1: Japanese encephalitis vaccine use in adults following a rapid schedule of 0 and 7 days is not an off-label use but rather an approved regimen for adults aged 18-65 years
Table 1: Japanese encephalitis vaccine use in children aged 2 months to 17 years is not an off-label use but rather an approved indication
Page 414: Under Japanese encephalitis vaccine, sentences 3-5 of the third paragraph should instead read: “Recently, JEV-VC has been approved for use in Canada in children ≥2 months of age (half a dose recommended for children aged ≥2 months to <3 years) on days 0, 28.33,36 The vaccine should be considered for pediatric travellers to endemic areas, as disease severity is high in this population.”32,36
Page 414: Under Japanese encephalitis vaccine, the second sentence of the fourth paragraph should instead read: “Recently, a rapid dosing schedule for adults aged 18 to 65 years has been approved for use in Canada, with a dose on day 0 and day 7 completed at least 1 week before risk of exposure, with seroconversion comparable to the 0- and 28-day schedule.”32,37
Readers should also note in Table 1 that the duration of protection conferred by the oral cholera/ETEC-diarrhea vaccine should read 3 months to 2 years.